Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cardiac dysfunction induced by trastuzumab].

Mario Campone1, Emmanuelle Bourbouloux, Pierre Fumoleau

  • 1Centre René-Gauducheau, Boulevard Jacques-Monod, 44805 Nantes Cedex. m-campone@nantes.fnclcc.fr

Bulletin Du Cancer
|May 19, 2005
PubMed
Summary

Trastuzumab improves outcomes for HER-2 positive metastatic breast cancer but can cause cardiac toxicity, especially with prior anthracycline use. Management strategies for this side effect are discussed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective SAJAC Study of Rehabilitation for Adolescents and Young Adults with Cancer in a Comprehensive Cancer Center.

Journal of adolescent and young adult oncology·2026
Same author

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Nature communications·2026
Same author

NOXA/MCL-1 axis determines cell-death decision between apoptosis and a GSDME-dependent cell death associated with production of inflammatory cytokines upon treatment of breast cancer cells with antimitotics.

Cell death & disease·2026
Same author

Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.

The oncologist·2026
Same author

When effective anticancer therapies are, in fact, destabilizing the tumor's Group Phenotypic Composition.

NPJ precision oncology·2026
Same author

Return to work among self-employed breast cancer survivors from the CANTO cohort.

Scientific reports·2026

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Context:

  • Trastuzumab enhances chemotherapy efficacy in HER-2 positive metastatic breast cancer.
  • Cardiac dysfunction is an identified side effect of Trastuzumab treatment.
  • Anthracycline exposure is linked to increased cardiac toxicity risk.

Purpose:

  • To review the incidence and mechanisms of Trastuzumab-induced cardiotoxicity.
  • To identify risk and predictive factors for cardiac dysfunction.
  • To outline patient management strategies for cardiotoxicity.

Summary:

  • Trastuzumab offers survival benefits but carries a risk of cardiac toxicity.
  • Cardiotoxicity incidence correlates with anthracycline exposure.
  • The precise mechanism of Trastuzumab cardiotoxicity remains under investigation.

Related Experiment Videos

Impact:

  • Informing clinical practice regarding Trastuzumab use in breast cancer patients.
  • Guiding risk assessment and monitoring for cardiac events.
  • Improving patient safety and outcomes in HER-2 positive breast cancer management.